Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sage Therapeutics, Inc.SAGE · Entity 77038 | Chief Business Officer | February 10, 2021 | February 12, 2021 |
| Sionna Therapeutics, Inc.SION · Entity 5996 | Director · President & CEO | September 17, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sage Therapeutics, Inc.
Report date February 10, 2021 · Filed February 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $82.27 · Expires 2031-02-10 | Direct | 19,000 |
Reported balance
After 2021-02-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-10 · Grant · Acquired 19,000 · Balance 19,000 F1: The securities awarded on February 10, 2021 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 4,750 shares of common stock shall vest on the one year anniversary of February 10, 2021, with 14,250 shares vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded on February 10, 2021 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 4,750 shares of common stock shall vest on the one year anniversary of February 10, 2021, with 14,250 shares vesting in 36 equal monthly installments thereafter.
Sionna Therapeutics, Inc.
Report date September 17, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 765,393 |
Ending reported balance
After 2026-09-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-17 · Grant · Acquired 109,025 · Balance 656,368 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest on June 17, 2027, subject to the Reporting Person's continued service with the Issuer as of the vesting date. Row 2 · 2026-09-17 · Grant · Acquired 109,025 · Balance 765,393 F2: Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest upon the achievement of a designated performance milestone, subject to the Reporting Person's continued service with the Issuer as of the vesting date. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.18 · Expires 2036-01-01 | Direct | 436,100 |
Reported balance
After 2026-09-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-17 · Grant · Acquired 436,100 · Balance 436,100 F3: The exercise price of the option is $7.18 per share, representing the fair market value per share of the Issuer's Common Stock on September 17, 2026 (the "Repricing Date"). Unless otherwise provided by the Issuer's board of directors or its compensation committee, if the option is exercised before the applicable retention period ends, the exercise price will revert to its original exercise price. The retention period begins on the Repricing Date and ends on the earliest of (i) the 18-month anniversary of the Repricing Date (March 17, 2028), (ii) a Sale Event (as defined in the Sionna Therapeutics, Inc. 2025 Stock Option and Incentive Plan (the "2025 Plan")) or (iii) certain qualifying terminations of service. F4: Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5: This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.21 · Expires 2036-01-01 | Direct | 0 |
Reported balance
After 2026-09-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-17 · Disposition to issuer · Disposed 436,100 · Balance 0 F4: Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5: This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest on June 17, 2027, subject to the Reporting Person's continued service with the Issuer as of the vesting date.
F2: Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest upon the achievement of a designated performance milestone, subject to the Reporting Person's continued service with the Issuer as of the vesting date.
F3: The exercise price of the option is $7.18 per share, representing the fair market value per share of the Issuer's Common Stock on September 17, 2026 (the "Repricing Date"). Unless otherwise provided by the Issuer's board of directors or its compensation committee, if the option is exercised before the applicable retention period ends, the exercise price will revert to its original exercise price. The retention period begins on the Repricing Date and ends on the earliest of (i) the 18-month anniversary of the Repricing Date (March 17, 2028), (ii) a Sale Event (as defined in the Sionna Therapeutics, Inc. 2025 Stock Option and Incentive Plan (the "2025 Plan")) or (iii) certain qualifying terminations of service.
F4: Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F5: This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
bluebird bio, Inc.
Report date June 02, 2025 · Filed June 03, 2025
Section 16 reporting ended · disclosed 2025-06-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-06-02 transaction · row 1
1 source rowRow 1 · 2025-06-02 · Disposition to issuer · Disposed 1,867 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F4: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price").
F2: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive
F4: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2026 Filed Sep 18, 2026 20:52 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 436,100 | $0.00 Strike: $39.21 | $0.00 |
DisclosureSEC source: 0001704336-26-000005 · edgardoc.xml · derivative · entry 4 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 436,100 shares Expires 2036-01-01 F4 · kind: Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · price: Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 20:52 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 436,100 | $0.00 Strike: $7.18 | $0.00 |
DisclosureSEC source: 0001704336-26-000005 · edgardoc.xml · derivative · entry 3 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 436,100 Underlying: Common Stock · 436,100 shares Expires 2036-01-01 F3 · derivative.exercise_price: The exercise price of the option is $7.18 per share, representing the fair market value per share of the Issuer's Common Stock on September 17, 2026 (the "Repricing Date"). Unless otherwise provided by the Issuer's board of directors or its compensation committee, if the option is exercised before the applicable retention period ends, the exercise price will revert to its original exercise price. The retention period begins on the Repricing Date and ends on the earliest of (i) the 18-month anniversary of the Repricing Date (March 17, 2028), (ii) a Sale Event (as defined in the Sionna Therapeutics, Inc. 2025 Stock Option and Incentive Plan (the "2025 Plan")) or (iii) certain qualifying terminations of service. F4 · kind: Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · price: Effective on the Repricing Date, the Issuer's board of directors approved an option repricing. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: This stock option award was issued pursuant to the 2025 Plan, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 20:52 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | GrantCommon Stock | 109,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001704336-26-000005 · edgardoc.xml · nonDerivative · entry 2 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 765,393 F2 · kind: Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest upon the achievement of a designated performance milestone, subject to the Reporting Person's continued service with the Issuer as of the vesting date. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 20:52 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | GrantCommon Stock | 109,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001704336-26-000005 · edgardoc.xml · nonDerivative · entry 1 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 656,368 F1 · kind: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest on June 17, 2027, subject to the Reporting Person's continued service with the Issuer as of the vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:19 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 436,100 | $0.00 Strike: $39.21 | $0.00 |
DisclosureSEC source: 0001704336-26-000002 · edgardoc.xml · derivative · entry 1 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 436,100 Underlying: Common Stock · 436,100 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 21:39 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 33,532 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001704336-25-000008 · edgardoc.xml · derivative · entry 12 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,142 Underlying: Common Stock · 33,532 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F6 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 21:39 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 22,895 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001704336-25-000008 · edgardoc.xml · derivative · entry 11 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,674 Underlying: Common Stock · 22,895 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F6 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 21:39 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,049 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001704336-25-000008 · edgardoc.xml · derivative · entry 10 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,569 Underlying: Common Stock · 30,049 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F6 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 21:39 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 13,324 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001704336-25-000008 · edgardoc.xml · derivative · entry 9 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,618 Underlying: Common Stock · 13,324 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F6 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 21:39 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 33,532 | $37.31 | $1,251,078.92 |
DisclosureSEC source: 0001704336-25-000008 · edgardoc.xml · nonDerivative · entry 8 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 547,343 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.00 to $37.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 21:39 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionCommon Stock | 33,532 | $6.11 | $204,880.52 |
DisclosureSEC source: 0001704336-25-000008 · edgardoc.xml · nonDerivative · entry 7 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 580,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 21:39 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 22,895 | $36.60 | $837,957.00 |
DisclosureSEC source: 0001704336-25-000008 · edgardoc.xml · nonDerivative · entry 6 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 547,343 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.00 to $36.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 21:39 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionCommon Stock | 22,895 | $6.11 | $139,888.45 |
DisclosureSEC source: 0001704336-25-000008 · edgardoc.xml · nonDerivative · entry 5 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 570,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 21:39 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 30,049 | $35.63 | $1,070,645.87 |
DisclosureSEC source: 0001704336-25-000008 · edgardoc.xml · nonDerivative · entry 4 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 547,343 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.00 to $35.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 21:39 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionCommon Stock | 30,049 | $6.11 | $183,599.39 |
DisclosureSEC source: 0001704336-25-000008 · edgardoc.xml · nonDerivative · entry 3 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 577,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 21:39 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 13,324 | $34.44 | $458,878.56 |
DisclosureSEC source: 0001704336-25-000008 · edgardoc.xml · nonDerivative · entry 2 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 547,343 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.00 to $34.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 21:39 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionCommon Stock | 13,324 | $6.11 | $81,409.64 |
DisclosureSEC source: 0001704336-25-000008 · edgardoc.xml · nonDerivative · entry 1 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 560,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. Read SEC document |
| October 16, 2025 Filed Oct 17, 2025 21:11 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 200 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001704336-25-000006 · edgardoc.xml · derivative · entry 9 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,942 Underlying: Common Stock · 200 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F4 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 16, 2025 Filed Oct 17, 2025 21:11 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,225 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001704336-25-000006 · edgardoc.xml · derivative · entry 8 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,142 Underlying: Common Stock · 10,225 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F4 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 16, 2025 Filed Oct 17, 2025 21:11 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 200 | $34.00 | $6,800.00 |
DisclosureSEC source: 0001704336-25-000006 · edgardoc.xml · nonDerivative · entry 6 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 547,343 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. Read SEC document |
| October 16, 2025 Filed Oct 17, 2025 21:11 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionCommon Stock | 200 | $6.11 | $1,222.00 |
DisclosureSEC source: 0001704336-25-000006 · edgardoc.xml · nonDerivative · entry 5 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 547,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. Read SEC document |
| October 16, 2025 Filed Oct 17, 2025 21:11 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 10,225 | $31.46 | $321,690.77 |
DisclosureSEC source: 0001704336-25-000006 · edgardoc.xml · nonDerivative · entry 4 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 547,343 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.07 to $31.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 16, 2025 Filed Oct 17, 2025 21:11 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionCommon Stock | 10,225 | $6.11 | $62,474.75 |
DisclosureSEC source: 0001704336-25-000006 · edgardoc.xml · nonDerivative · entry 3 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 557,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 21:11 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 14,775 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001704336-25-000006 · edgardoc.xml · derivative · entry 7 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,367 Underlying: Common Stock · 14,775 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F4 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 21:11 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 14,775 | $31.11 | $459,662.07 |
DisclosureSEC source: 0001704336-25-000006 · edgardoc.xml · nonDerivative · entry 2 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 547,343 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.00 to $31.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 21:11 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionCommon Stock | 14,775 | $6.11 | $90,275.25 |
DisclosureSEC source: 0001704336-25-000006 · edgardoc.xml · nonDerivative · entry 1 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 562,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 20:09 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,793 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001704336-25-000004 · edgardoc.xml · derivative · entry 6 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,142 Underlying: Common Stock · 7,793 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F4 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 20:09 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 7,793 | $29.70 | $231,451.32 |
DisclosureSEC source: 0001704336-25-000004 · edgardoc.xml · nonDerivative · entry 4 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 547,343 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.83 to $29.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 20:09 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionCommon Stock | 7,793 | $6.11 | $47,615.23 |
DisclosureSEC source: 0001704336-25-000004 · edgardoc.xml · nonDerivative · entry 3 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 555,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 20:09 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 17,207 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001704336-25-000004 · edgardoc.xml · derivative · entry 5 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,935 Underlying: Common Stock · 17,207 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F4 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 20:09 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 17,207 | $28.85 | $496,346.24 |
DisclosureSEC source: 0001704336-25-000004 · edgardoc.xml · nonDerivative · entry 2 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 547,343 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.75 to $28.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 20:09 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionCommon Stock | 17,207 | $6.11 | $105,134.77 |
DisclosureSEC source: 0001704336-25-000004 · edgardoc.xml · nonDerivative · entry 1 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 564,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 21:40 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,426 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0002036042-25-000051 · edgardoc.xml · derivative · entry 6 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,142 Underlying: Common Stock · 7,426 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F4 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 21:40 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 7,426 | $25.01 | $185,713.86 |
DisclosureSEC source: 0002036042-25-000051 · edgardoc.xml · nonDerivative · entry 4 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 547,343 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.80 to $25.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 21:40 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionCommon Stock | 7,426 | $6.11 | $45,372.86 |
DisclosureSEC source: 0002036042-25-000051 · edgardoc.xml · nonDerivative · entry 3 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 554,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 21:40 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 17,574 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0002036042-25-000051 · edgardoc.xml · derivative · entry 5 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,568 Underlying: Common Stock · 17,574 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F4 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 21:40 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 17,574 | $24.96 | $438,647.04 |
DisclosureSEC source: 0002036042-25-000051 · edgardoc.xml · nonDerivative · entry 2 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 547,343 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.75 to $25.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 21:40 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionCommon Stock | 17,574 | $6.11 | $107,377.14 |
DisclosureSEC source: 0002036042-25-000051 · edgardoc.xml · nonDerivative · entry 1 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 564,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. Read SEC document |
| August 20, 2025 Filed Aug 21, 2025 20:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001482981-25-000144 · edgardoc.xml · derivative · entry 3 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 228,142 Underlying: Common Stock · 25,000 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F3 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| August 20, 2025 Filed Aug 21, 2025 20:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | SaleCommon Stock | 25,000 | $22.75 | $568,750.00 |
DisclosureSEC source: 0001482981-25-000144 · edgardoc.xml · nonDerivative · entry 2 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 547,343 F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.0700 to $23.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 20, 2025 Filed Aug 21, 2025 20:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | Exercise / conversionCommon Stock | 25,000 | $6.11 | $152,750.00 |
DisclosureSEC source: 0001482981-25-000144 · edgardoc.xml · nonDerivative · entry 1 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 572,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 17:11 UTC | bluebird bio, Inc. BLUE · Entity 78923 | Disposition to issuerCommon Stock | 1,867 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-081105 · ownership.xml · nonDerivative · entry 1 Cloonan Michael · CIK 0001704336 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of February 21, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Beacon Parent Holdings, L.P. ("Parent") and Beacon Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. Tendering stockholders were given the option to receive per share consideration of either (x) $3.00 in cash per share, subject to any applicable withholding taxes and without interest thereon, plus one contingent value right ("CVR") per share, representing the right to receive one contingent payment of $6.84, in cash, subject to any applicable withholding taxes and without interest thereon, upon achievement of the specified milestone or (y) $5.00 in cash per share, subject to any applicable withholding taxes and without interest thereon (collectively, the "Offer Price"). F2 · price: (Continued from footnote 1) After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of June 2, 2025 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each time-based restricted stock unit award with respect to shares that is, at the time of determination, subject to vesting or forfeiture conditions and that is not a PSU Award (as defined below) (but including, for clarity, any PSU Award that is subject solely to service-based vesting conditions as of the Effective Time) ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive F4 · price: (Continued from footnote 3) (i) an amount in cash equal to the product of the number of shares underlying such RSU Award immediately prior to the Effective Time and $3.00 in cash, subject to any applicable withholding taxes and without interest thereon plus (ii) one CVR with respect to each share subject to such RSU Award immediately prior to the Effective Time. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 21:05 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | GrantStock Option (Right to Buy) · Derivative | 450,252 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000950170-25-017034 · ownership.xml · derivative · entry 1 Cloonan Michael · CIK 0001704336 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,252 Underlying: Common Stock · 450,252 shares Expires 2035-02-05 F1 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 16:06 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantCommon Stock | 37,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-007127 · primarydocument.xml · nonDerivative · entry 1 Cloonan Michael · CIK 0001704336 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,350 F1 · security: These restricted stock units for common stock vest ratably over three years in annual installments commencing on June 20, 2024. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 17:20 UTC | bluebird bio, Inc. BLUE · Entity 78923 | GrantStock Option (right to buy) · Derivative | 74,775 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0000950170-24-076894 · ownership.xml · derivative · entry 1 Cloonan Michael · CIK 0001704336 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,775 Underlying: Common Stock · 74,775 shares Expires 2034-06-20 F1 · derivative.exercise_date: The stock option vests with respect to one third of the shares on each of the first three anniversaries of the grant date. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 16:01 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $82.27 | $0.00 |
DisclosureSEC source: 0001562180-21-001123 · primarydocument.xml · derivative · entry 1 Cloonan Michael · CIK 0001704336 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2031-02-10 F1 · derivative.exercise_date: The securities awarded on February 10, 2021 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 4,750 shares of common stock shall vest on the one year anniversary of February 10, 2021, with 14,250 shares vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 01, 2020 Filed May 5, 2020 16:58 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $37.13 | $0.00 |
DisclosureSEC source: 0001562180-20-003386 · primarydocument.xml · derivative · entry 1 Cloonan Michael · CIK 0001704336 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-05-01 F1 · derivative.exercise_date: The securities awarded on May 1, 2020 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 12,500 shares of common stock shall vest on the one year anniversary of May 1, 2020, with 37,500 shares vesting in 36 equal monthly installments thereafter. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 16:44 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 9,450 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0001562180-20-003224 · primarydocument.xml · derivative · entry 1 Cloonan Michael · CIK 0001704336 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,450 Underlying: Common Stock · 9,450 shares Expires 2030-04-28 F1 · derivative.exercise_date: The securities awarded on April 28, 2020 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. 25% of the shares of common stock underlying this stock option award will vest on April 28, 2021, and the remaining 75% of the shares of common stock underlying this stock option award will vest on April 28, 2022, subject, in each case, to the Reporting Person's continued employment with the Issuer on each of the applicable vesting dates. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 16:56 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $68.87 | $0.00 |
DisclosureSEC source: 0001562180-20-001242 · primarydocument.xml · derivative · entry 1 Cloonan Michael · CIK 0001704336 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2030-02-12 F1 · derivative.exercise_date: The securities awarded on February 12, 2020 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 5,625 shares of common stock shall vest on the one year anniversary of February 12, 2020, with 16,875 shares vesting in 36 equal monthly installments thereafter. Read SEC document |
| July 25, 2019 Filed Jul 29, 2019 20:00 UTC | Sage Therapeutics, Inc. SAGE · Entity 77038 | Tax withholdingCommon Stock | 1,088 | $161.38 | $175,581.44 |
DisclosureSEC source: 0001562180-19-004093 · primarydocument.xml · nonDerivative · entry 2 Cloonan Michael · CIK 0001704336 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,102 F2 · balance_after: Reflects beneficial ownership balance which includes 279 ESPP shares purchased on June 30, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.